Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia.
- Deenik, W.
- Janssen, J.J.M.
- Holt, B. van der
- Verhoef, G.E.
- Smit, W.M.
- Kersten, M.J.
- Daenen, S.M.G.J.
- Verdonck, L.F.
- Ferrant, A.
- Schattenberg, A.V.M.B.
- Sonneveld, P.
- Marwijk Kooy, M. van
- Wittebol, S.
- Willemze, R.
- Wijermans, P.W.
- Beverloo, H.B.
- Lowenberg, B.
- Valk, P.J.
- Ossenkoppele, G.J.
- Cornelissen, J.J.
DOIAbstract
BACKGROUND: In order to improve the molecular response rate and prevent resistance to treatment, combination therapy with different dosages of imatinib and cytarabine was studied in newly diagnosed patients with chronic myeloid leukemia in the HOVON-51 study. DESIGN AND METHODS: Having reported feasibility previously, we hereby report the efficacy of escalated imatinib (200 mg, 400 mg, 600 mg or 800 mg) in combination with two cycles of intravenous cytarabine (200 mg/m(2) or 1000 mg/m(2) days 1 to 7) in 162 patients with chronic myeloid leukemia. RESULTS: With a median follow-up of 55 months, the 5-year cumulative incidences of complete cytogenetic response, major molecular response, and complete molecular response were 89%, 71%, and 53%, r...
Add to ORKG